Stereotactic radiotherapy for early-stage non-small cell lung cancer

Abstract

Surgical resection is treatment of choice for early stage non-small cell lung cancer, even though 20%-30% of patients do not undergo surgery. Compared to conventional fractionated radiotherapy, stereotactic body radiotherapy (SBRT) has demonstrated excellent local control (LC) and overall survival (OS). Central and ultra-central lesions present higher toxicity rates after SBRT because of their proximity to mediastinal structures. Dose escalation studies have documented that 10-12 Gy per fraction is the maximal tolerable dose with acceptable rates of treatment adverse events and survival. Peripheral lesions can be safely treated with high radiotherapy dose (biologically equivalent dose of ≥ 150 Gy) and a different SBRT dose schedule has showed comparable results with LC rates > 90% and OS comparable to surgical resection. Elderly patients, defined as 75 years or older, are a subgroup of patients who may benefit the most from SBRT, as they have higher morbidity and mortality risks because of comorbidities and decreased lung function. At present, there are no randomized studies comparing SBRT with surgery for patients who are potential candidates for surgical removal. Retrospective studies and systematic reviews have showed encouraging results in terms of cancer-specific survival and LC.

Keywords

SBRT / ablative radiotherapy / early stage non-small cell lung cancer / NSCLC

References

[1] McGarry RC,des Rosiers P.Observation-only management of early stage, medically inoperable lung cancer: poor outcome..Chest2002;121:1155-8

[2] Raz DJ,Ou SH.Natural history of stage I non-small cell lung cancer: implications for early detection..Chest2007;132:193-9

[3] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer, version 3. 2020. Available from: https://www.nccn.org/ [Last accessed on 12 Jun 2020]

[4] Postmus P,Oudkerk M,Waller D.Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2017;28:iv1-21

[5] Robinson CG.The treatment of early-stage disease..Semin Radiat Oncol2010;20:178-85

[6] Nyman J,Lund JA,Bergman B.SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC..Radiother Oncol2016;121:1-8

[7] Ball D,Vinod S,Ruben J.Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial..Lancet Oncol2019;20:494-503

[8] Onishi H,Nagata Y,Fujino M.Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study..J Thorac Oncol2007;2:S94-100

[9] Bradley JD,Drzymala RE,Jones G.Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant..Int J Radiat Oncol Biol Phys2010;77:1146-50

[10] Timmerman R,Yiannoutsos L.Excessive toxicity when treating central tumors in a phase ii study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.J Clin Oncol2006;24:4833-9

[11] Timmerman R,Galvin J,Straube W.Stereotactic body radiation therapy for inoperable early stage lung cancer..JAMA2010;303:1070-6 PMCID:PMC2907644

[12] Timmerman RD,Pass HI,Edelman MJ.Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial..JAMA Oncol2018;4:1263-6 PMCID:PMC6117102

[13] Eriguchi T,Sanuki N,Aoki Y.Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer..Lung Cancer2017;109:62-7

[14] Guckenberger M,Dieckmann K,Hoyer M.ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer..Radiother Oncol2017;124:11-7

[15] Videtic GM,Singh AK,Parker W.A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)..Int J Radiat Oncol Biol Phys2015;93:757-64 PMCID:PMC4744654

[16] Singh AK,Stephans KL,Hermann GM.One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial..Int J Radiat Oncol Biol Phys2019;105:752-9 PMCID:PMC7043929

[17] Ma SJ,Serra LM,Hermann GM.Three- versus five-fraction regimens of stereotactic body radiotherapy for peripheral early-stage non-small-cell lung cancer: a two-institution propensity score-matched analysis..Clin Lung Cancer2018;19:e297-302

[18] Cummings MA,Hermann G,Syed Y.Comparison of single- and five-fraction regimens of stereotactic body radiation therapy for peripheral early-stage non-small-cell lung cancer: a two-institution propensity-matched analysis..Clin Lung Cancer2018;19:511-7

[19] Stephans KL,Reddy CA,Magnelli A.Tumor control and toxicity for common stereotactic body radiation therapy dose-fractionation regimens in stage I non-small cell lung cancer..Int J Radiat Oncol Biol Phys2018;100:462-9

[20] Roach MC,DeWees TA,Przybysz D.Stereotactic body radiation therapy for central early-stage NSCLC: results of a prospective phase I/II trial..J Thorac Oncol2018;13:1727-32

[21] Bezjak A,Gaspar LE,Straube WL.Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial..J Clin Oncol2019;37:1316-25 PMCID:PMC6524984

[22] Tekatli H,Dahele M,Verbakel W.Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “Ultracentral” non-small cell lung cancer..J Thorac Oncol2016;11:1081-9

[23] Zhao Y,Thomas S,Dunne EM.Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors..Radiat Oncol2020;15:50 PMCID:PMC7047404

[24] Dalwadi SM,Bernicker EH,Teh BS.Practice patterns and outcomes in elderly stage I non-small-cell lung cancer: a 2004 to 2012 SEER analysis..Clin Lung Cancer2018;19:e269-76

[25] Brooks ED,Zhao L,Liao Z.Stereotactic ablative radiation therapy is highly safe and effective for elderly patients with early-stage non-small cell lung cancer..Int J Radiat Oncol Biol Phys2017;98:900-7 PMCID:PMC5881567

[26] Kreinbrink P,Tolekidis G,Sher D.Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): extremely safe and effective..J Geriatr Oncol2017;8:351-5

[27] Cassidy RJ,Zhang X,Switchenko JM.Stereotactic body radiotherapy for early-stage non-small-cell lung cancer in patients 80 years and older: a multi-center analysis..Clin Lung Cancer2017;18:551-8.e6 PMCID:PMC5783539

[28] Videtic GMM,Reddy CA.Never too old: a single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer..Pract Radiat Oncol2017;7:e543-9

[29] Chang JY,Paul MA,Louie AV.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials..Lancet Oncol2015;16:630-7 PMCID:PMC4489408

[30] Guckenberger M,Van Schil P.The American Society of Clinical Oncology-endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non-small cell lung cancer: an expert opinion..J Thorac Cardiovasc Surg2019;157:358-61

[31] Whitson BA,Duval SJ,Maddaus MA.Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy..Ann Thorac Surg2008;86:2008-16discussion 2016-8

[32] Zhang B,Ma X,Cao D.Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis..Radiother Oncol2014;112:250-5

[33] Wang SW,Zhou Q,Xia WJ.Stereotactic ablative radiotherapy versus lobectomy for stage I non-small cell lung cancer: a systematic review..Thorac Cancer2018;9:337-47 PMCID:PMC5832478

[34] Scotti V,Francolini G,Vasilyeva P.Stereotactic ablative radiotherapy as an alternative to lobectomy in patients with medically operable stage I NSCLC: a retrospective, multicenter analysis..Clin Lung Cancer2019;20:e53-61

[35] Robinson CG,El Naqa IM,Olsen JR.Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer..J Thorac Oncol2013;8:192-201

[36] Chen H,Boldt RG,Palma DA.Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies..Int J Radiat Oncol Biol Phys2018;101:186-94

[37] Khakwani A,Beckett P,Navani N.Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England..Thorax2020;75:237-43

[38] Cao C,Chung C,Rimner A.A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer..J Thorac Cardiovasc Surg2019;157:362-73.e8 PMCID:PMC6582640

[39] Ezer N,Mhango G,Powell CA.Outcomes after stereotactic body radiotherapy versus limited resection in older patients with early-stage lung cancer..J Thorac Oncol2015;10:1201-6 PMCID:PMC4511922

[40] Grills IS,Welsh R,McInerney E.Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer..J Clin Oncol2010;28:928-35

[41] Wu J,Chan L,Zhang PJ.Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage non-small cell lung cancer: a national cancer database study..J Thorac Cardiovasc Surg2019;

[42] Yerokun BA,Gulack BC,Mulvihill MS.A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer..J Thorac Cardiovasc Surg2017;154:675-86.e4